Groetzinger Lara M, Williams Julia, Svec Susan, Donahoe Michael P, Lamberty Phillip E, Barbash Ian J
Department of Pharmacy, UPMC Presbyterian Hospital, Pittsburgh, PA, USA.
Department of Nursing, UPMC Presbyterian Hospital, Pittsburgh, PA, USA.
Ann Pharmacother. 2022 Jul;56(7):773-781. doi: 10.1177/10600280211053318. Epub 2021 Oct 21.
Reducing central venous catheter (CVC) utilization can reduce complications in the intensive care unit (ICU). While norepinephrine (NE) is traditionally administered via a CVC, lower concentrations may be safely administered via peripheral intravenous (PIV) lines.
We aimed to describe the implementation of a pilot protocol utilizing PIVs to administer a low-dose and lower-concentration NE, review the number of CVCs avoided, and evaluate any adverse events.
In a quaternary medical intensive care unit (MICU), from March 1, 2019, to February 29, 2020, we reviewed charts for CVC placement and adverse events from the pNE infusion. We also measured unit-level CVC utilization in all MICU patients and assessed the change in utilization associated with the peripheral norepinephrine (pNE) protocol.
Over a 1-year period, 87 patients received a pNE infusion. Overall, 44 patients (51%) never required CVC placement during their MICU stay. Three patients (3%) experienced adverse events, none of which were documented as serious and or required antidote for treatment. Implementation of the protocol was associated with a decrease in the number of patients at the unit level who received CVCs, even if they did not receive pNE.
In this small pilot study, we pragmatically demonstrated that pNE is safe and may reduce the need for CVC placement. This information can be used to aid in pNE protocol development and implementation at other institutions, but further research should be done to confirm the safety of routine use of pNE in clinical practice.
减少中心静脉导管(CVC)的使用可降低重症监护病房(ICU)的并发症。虽然去甲肾上腺素(NE)传统上是通过CVC给药,但较低浓度的NE可通过外周静脉(PIV)通路安全给药。
我们旨在描述一项试点方案的实施情况,该方案利用PIV给予低剂量和低浓度的NE,回顾避免使用CVC的数量,并评估任何不良事件。
在一家四级医疗重症监护病房(MICU),从2019年3月1日至2020年2月29日,我们查阅了CVC置管图表以及来自外周去甲肾上腺素(pNE)输注的不良事件。我们还测量了所有MICU患者的科室层面CVC使用率,并评估了与外周去甲肾上腺素(pNE)方案相关的使用率变化。
在1年期间,87例患者接受了pNE输注。总体而言,44例患者(51%)在其MICU住院期间从未需要进行CVC置管。3例患者(3%)发生了不良事件,均未记录为严重事件,也无需使用解毒剂进行治疗。该方案的实施与科室层面接受CVC置管的患者数量减少相关,即使他们未接受pNE。
在这项小型试点研究中,我们切实证明了pNE是安全的,并且可能减少CVC置管的需求。这些信息可用于帮助其他机构制定和实施pNE方案,但应开展进一步研究以确认pNE在临床实践中常规使用的安全性。